These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1140 related articles for article (PubMed ID: 11687850)

  • 1. Tissue- and urokinase-type plasminogen activators and type 1 plasminogen activator inhibitor in melanomas and benign skin pigment neoplasms.
    Gershtein ES; Medvedeva SV; Babkina IV; Kushlinskii NE; Trapeznikov NN
    Bull Exp Biol Med; 2001 Jul; 132(1):670-4. PubMed ID: 11687850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
    Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
    Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urokinase and tissue plasminogen activators and their inhibitor PAI-1 in human tumors.
    Gershtein ES; Kushlinskii NE
    Bull Exp Biol Med; 2001 Jan; 131(1):67-72. PubMed ID: 11329087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice.
    de Vries TJ; Kitson JL; Silvers WK; Mintz B
    Cancer Res; 1995 Oct; 55(20):4681-7. PubMed ID: 7553649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spitz naevi may express components of the plasminogen activation system.
    Ferrier CM; Van Geloof WL; Straatman H; Van De Molengraft FJ; Van Muijen GN; Ruiter DJ
    J Pathol; 2002 Sep; 198(1):92-9. PubMed ID: 12210068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasminogen activation in melanocytic neoplasia.
    Delbaldo C; Masouye I; Saurat JH; Vassalli JD; Sappino AP
    Cancer Res; 1994 Aug; 54(16):4547-52. PubMed ID: 8044805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Plasminogen activators of urokinase and tissue types and their inhibitor (PAI-1) in cytosol fraction in thyroid diseases].
    Kushlinskiĭ NE; Gershteĭn ES; Kazantseva IA; Kharitidi TIu; Liakina LT; Kazakov SP; Bagatyrev OP; Kalinin AP
    Vestn Ross Akad Med Nauk; 2001; (5):32-4. PubMed ID: 11510147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma.
    Häckel C; Czerniak B; Ayala AG; Radig K; Roessner A
    Cancer; 1997 Jan; 79(1):53-8. PubMed ID: 8988726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production of urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor-1 (PAI-1) in human brain tumours.
    Arai Y; Kubota T; Nakagawa T; Kabuto M; Sato K; Kobayashi H
    Acta Neurochir (Wien); 1998; 140(4):377-85; discussion 385-6. PubMed ID: 9689330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasminogen activators and their inhibitor in bone tumors and tumor-like damages.
    Kushlinskii NE; Yusifov AI; Gershtein ES; Solov'ev YN; Trapeznikov NN
    Bull Exp Biol Med; 2001 Aug; 132(2):780-2. PubMed ID: 11713566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urokinase and tissue plasminogen activators and their PAI-1 inhibitor in tumors of patients with oral mucosal cancer: relationship with the main clinical morphological factors.
    Gershtein ES; Batsev AF; Matyakin EG; Kushlinskii NE
    Bull Exp Biol Med; 2010 Sep; 149(3):347-50. PubMed ID: 21246098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis.
    Sier CF; Vloedgraven HJ; Ganesh S; Griffioen G; Quax PH; Verheijen JH; Dooijewaard G; Welvaart K; van de Velde CJ; Lamers CB
    Gastroenterology; 1994 Nov; 107(5):1449-56. PubMed ID: 7926508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
    De Vries TJ; Mooy CM; Van Balken MR; Luyten GP; Quax PH; Verspaget HW; Weidle UH; Ruiter DJ; Van Muijen GN
    J Pathol; 1995 Jan; 175(1):59-67. PubMed ID: 7891228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
    Quax PH; van Muijen GN; Weening-Verhoeff EJ; Lund LR; Danø K; Ruiter DJ; Verheijen JH
    J Cell Biol; 1991 Oct; 115(1):191-9. PubMed ID: 1918136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low levels of urokinase plasminogen activator components in basal cell carcinoma of the skin.
    Maguire T; Chin D; Soutar D; Duffy MJ
    Int J Cancer; 2000 Feb; 85(4):457-9. PubMed ID: 10699914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxygen modulates the release of urokinase and plasminogen activator inhibitor-1 by retinal pigment epithelial cells.
    Erichsen JT; Jarvis-Evans J; Khaliq A; Boulton M
    Int J Biochem Cell Biol; 2001 Mar; 33(3):237-47. PubMed ID: 11311855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation and interactions in the activation of cell-associated plasminogen.
    Myöhänen H; Vaheri A
    Cell Mol Life Sci; 2004 Nov; 61(22):2840-58. PubMed ID: 15558213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming growth factor-beta1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system.
    Ramont L; Pasco S; Hornebeck W; Maquart FX; Monboisse JC
    Exp Cell Res; 2003 Nov; 291(1):1-10. PubMed ID: 14597403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers.
    Weckroth M; Vaheri A; Virolainen S; Saarialho-Kere U; Jahkola T; Sirén V
    Br J Dermatol; 2004 Dec; 151(6):1189-96. PubMed ID: 15606514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of urokinase-type plasminogen activator and its inhibitor PAI-1 in gastric cancer.
    Herszényi L; Plebani M; Cardin R; Carraro P; De Paoli M; Roveroni G; Naccarato R; Farinati F
    Acta Physiol Hung; 1995; 83(3):213-21. PubMed ID: 8852646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.